vs

Side-by-side financial comparison of Royalty Pharma plc (RPRX) and VALVOLINE INC (VVV). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $461.8M, roughly 1.3× VALVOLINE INC). Royalty Pharma plc runs the higher net margin — 34.4% vs -7.1%, a 41.5% gap on every dollar of revenue. On growth, VALVOLINE INC posted the faster year-over-year revenue change (11.5% vs 4.8%). Over the past eight quarters, VALVOLINE INC's revenue compounded faster (9.0% CAGR vs 4.6%).

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Valvoline Inc. is an American retail automotive services company based in Lexington, Kentucky. It licenses the name for a number of Valvoline-labeled automotive oil, additives, and lubricants. It also owns the Valvoline Instant Oil Change, Great Canadian Oil Change and Valvoline Express Care car repair chains. As of 2023, it is the second largest oil change service provider in the United States with 10% market share and over 1,650 locations.

RPRX vs VVV — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.3× larger
RPRX
$622.0M
$461.8M
VVV
Growing faster (revenue YoY)
VVV
VVV
+6.7% gap
VVV
11.5%
4.8%
RPRX
Higher net margin
RPRX
RPRX
41.5% more per $
RPRX
34.4%
-7.1%
VVV
Faster 2-yr revenue CAGR
VVV
VVV
Annualised
VVV
9.0%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
RPRX
RPRX
VVV
VVV
Revenue
$622.0M
$461.8M
Net Profit
$214.2M
$-32.8M
Gross Margin
37.4%
Operating Margin
62.4%
4.0%
Net Margin
34.4%
-7.1%
Revenue YoY
4.8%
11.5%
Net Profit YoY
2.9%
-135.8%
EPS (diluted)
$0.49
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPRX
RPRX
VVV
VVV
Q4 25
$622.0M
$461.8M
Q3 25
$609.3M
$453.8M
Q2 25
$578.7M
$439.0M
Q1 25
$568.2M
$403.2M
Q4 24
$593.6M
$414.3M
Q3 24
$564.7M
$435.5M
Q2 24
$537.3M
$421.4M
Q1 24
$568.0M
$388.7M
Net Profit
RPRX
RPRX
VVV
VVV
Q4 25
$214.2M
$-32.8M
Q3 25
$288.2M
$25.0M
Q2 25
$30.2M
$56.5M
Q1 25
$238.3M
$37.6M
Q4 24
$208.2M
$91.6M
Q3 24
$544.0M
$92.3M
Q2 24
$102.0M
$45.9M
Q1 24
$4.8M
$41.4M
Gross Margin
RPRX
RPRX
VVV
VVV
Q4 25
37.4%
Q3 25
39.1%
Q2 25
40.5%
Q1 25
37.3%
Q4 24
36.9%
Q3 24
39.1%
Q2 24
39.7%
Q1 24
37.6%
Operating Margin
RPRX
RPRX
VVV
VVV
Q4 25
62.4%
4.0%
Q3 25
70.1%
18.6%
Q2 25
36.3%
21.6%
Q1 25
94.0%
16.6%
Q4 24
60.9%
34.7%
Q3 24
30.9%
Q2 24
50.2%
22.2%
Q1 24
-13.0%
19.7%
Net Margin
RPRX
RPRX
VVV
VVV
Q4 25
34.4%
-7.1%
Q3 25
47.3%
5.5%
Q2 25
5.2%
12.9%
Q1 25
41.9%
9.3%
Q4 24
35.1%
22.1%
Q3 24
96.3%
21.2%
Q2 24
19.0%
10.9%
Q1 24
0.8%
10.7%
EPS (diluted)
RPRX
RPRX
VVV
VVV
Q4 25
$0.49
$-0.26
Q3 25
$0.67
$0.20
Q2 25
$0.07
$0.44
Q1 25
$0.55
$0.29
Q4 24
$0.46
$0.71
Q3 24
$1.21
$0.70
Q2 24
$0.23
$0.35
Q1 24
$0.01
$0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPRX
RPRX
VVV
VVV
Cash + ST InvestmentsLiquidity on hand
$618.7M
$69.9M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.7B
$307.6M
Total Assets
$19.6B
$3.4B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPRX
RPRX
VVV
VVV
Q4 25
$618.7M
$69.9M
Q3 25
$938.9M
$51.6M
Q2 25
$631.9M
$68.3M
Q1 25
$1.1B
$61.9M
Q4 24
$929.0M
$60.0M
Q3 24
$950.1M
$68.3M
Q2 24
$1.8B
$65.7M
Q1 24
$843.0M
$494.5M
Total Debt
RPRX
RPRX
VVV
VVV
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
RPRX
RPRX
VVV
VVV
Q4 25
$9.7B
$307.6M
Q3 25
$9.6B
$338.5M
Q2 25
$9.5B
$313.6M
Q1 25
$9.8B
$248.7M
Q4 24
$10.3B
$229.8M
Q3 24
$10.3B
$185.6M
Q2 24
$9.8B
$106.5M
Q1 24
$9.9B
$60.1M
Total Assets
RPRX
RPRX
VVV
VVV
Q4 25
$19.6B
$3.4B
Q3 25
$19.3B
$2.7B
Q2 25
$18.3B
$2.6B
Q1 25
$17.6B
$2.5B
Q4 24
$18.2B
$2.3B
Q3 24
$18.0B
$2.4B
Q2 24
$17.7B
$2.4B
Q1 24
$16.1B
$2.8B
Debt / Equity
RPRX
RPRX
VVV
VVV
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPRX
RPRX
VVV
VVV
Operating Cash FlowLast quarter
$827.1M
$64.8M
Free Cash FlowOCF − Capex
$7.4M
FCF MarginFCF / Revenue
1.6%
Capex IntensityCapex / Revenue
12.4%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters
$57.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPRX
RPRX
VVV
VVV
Q4 25
$827.1M
$64.8M
Q3 25
$702.6M
$121.9M
Q2 25
$364.0M
$86.9M
Q1 25
$596.1M
$47.2M
Q4 24
$742.5M
$41.2M
Q3 24
$703.6M
$101.3M
Q2 24
$658.2M
$75.6M
Q1 24
$664.6M
$68.3M
Free Cash Flow
RPRX
RPRX
VVV
VVV
Q4 25
$7.4M
Q3 25
$23.0M
Q2 25
$32.0M
Q1 25
$-4.6M
Q4 24
$-12.4M
Q3 24
$29.9M
Q2 24
$9.8M
Q1 24
$23.4M
FCF Margin
RPRX
RPRX
VVV
VVV
Q4 25
1.6%
Q3 25
5.1%
Q2 25
7.3%
Q1 25
-1.1%
Q4 24
-3.0%
Q3 24
6.9%
Q2 24
2.3%
Q1 24
6.0%
Capex Intensity
RPRX
RPRX
VVV
VVV
Q4 25
12.4%
Q3 25
21.8%
Q2 25
12.5%
Q1 25
12.8%
Q4 24
12.9%
Q3 24
16.4%
Q2 24
15.6%
Q1 24
11.6%
Cash Conversion
RPRX
RPRX
VVV
VVV
Q4 25
3.86×
Q3 25
2.44×
4.88×
Q2 25
12.06×
1.54×
Q1 25
2.50×
1.26×
Q4 24
3.57×
0.45×
Q3 24
1.29×
1.10×
Q2 24
6.45×
1.65×
Q1 24
139.10×
1.65×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

VVV
VVV

Oil Change And Related Fees$337.7M73%
Non Oil Change And Related Fees$100.5M22%
Franchise Fees And Other$23.6M5%

Related Comparisons